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Functional interaction between telomere
protein TPP1 and telomerase
Arthur J. Zaug, Elaine R. Podell, Jayakrishnan Nandakumar, and Thomas R. Cech1
Department of Chemistry and Biochemistry, Howard Hughes Medical Institute, University of Colorado, Boulder,
Colorado 80309, USA
Human chromosome end-capping and telomerase regulation require POT1 (Protection of Telomeres 1) and TPP1
proteins, which bind to the 39 ssDNA extension of human telomeres. POT1–TPP1 binding to telomeric DNA
activates telomerase repeat addition processivity. We now provide evidence that this POT1–TPP1 activation
requires specific interactions with telomerase, rather than it being a DNA substrate-specific effect. First,
telomerase from the fish medaka, which extends the same telomeric DNA primer as human telomerase, was not
activated by human POT1–TPP1. Second, mutation of a conserved glycine, Gly100 in the TEN (telomerase
essential N-terminal) domain of TERT, abolished the enhancement of telomerase processivity by POT1–TPP1, in
contrast to other single amino acid mutations. Chimeric human–fish telomerases that contained the human
TEN domain were active but not stimulated by POT1–TPP1, showing that additional determinants of processivity
lie outside the TEN domain. Finally, primers bound to mouse POT1A and human TPP1 were activated for
extension by human telomerase, whereas mPOT1A–mTPP1 was most active with mouse telomerase, indicating
that these mammalian telomerases have specificity for their respective TPP1 proteins. We suggest that
a sequence-specific interaction between TPP1 in the TPP1–POT1–telomeric DNA complex and the G100 region of
the TEN domain of TERT is necessary for high-processivity telomerase action.
[Keywords: Chromosome end-capping; POT1–TPP1; processivity; telomerase; telomeres]
Supplemental material is available at http://www.genesdev.org.
Received November 3, 2009; revised version accepted February 4, 2010.
Telomeres, the very ends of linear chromosomes, are po-
tential sites of genome instability. Chromosome ends
are therefore capped by proteins that bind to either the
double-stranded telomeric DNA repeats or the single-
stranded 39 extension at the very end of the chromosome.
The importance of 39 end-capping is illustrated by the
dramatic phenotype of deletion of pot1 (Protection of
Telomeres 1) in Schizosaccharomyces pombe: Telomeric
DNA is eroded, chromosome ends undergo random fu-
sion, most cells die, and the rare survivors have all three
of their chromosomes circularized, which allows vegeta-
tive life without telomeres (Baumann and Cech 2001;
Wang and Baumann 2008).
The situation is more subtle in mammals. RNAi knock-
down of human POT1 in transformed human cells causes
an increase in telomere associations that are thought to
indicate chromosome end fusions (Veldman et al. 2004),
although the frequency of such events is much less than
that obtained by inhibition of the double-stranded telo-
meric DNA-binding protein TRF2 (Hockemeyer et al.
2005). In addition, upon reduction of hPOT1, all telomeres
show a transient DNA damage response in the G1 phase of
the cell cycle (Hockemeyer et al. 2005), and similar results
have been obtained in chicken cells (Churikov et al. 2006).
In the mouse, where a complete knockout can be studied,
there are two POT1 genes (Hockemeyer et al. 2006).
POT1A (but not POT1B) is required to repress a DNA
damage signal at telomeres (Hockemeyer et al. 2006; Wu
et al. 2006). Mouse POT1A represses the DNA damage re-
sponse that occurs through ATR (ataxia telangiectasia and
Rad3-related) kinase signaling, whereas TRF2 represses
DNA damage response through ATM (ataxia telangiecta-
sia mutated) kinase signaling (Denchi and de Lange 2007).
Another telomeric protein, TPP1 (Houghtaling et al.
2004; Liu et al. 2004; Ye et al. 2004), is the heterodimeric
partner of POT1 (Wang et al. 2007; Xin et al. 2007). The
POT1–TPP1 complex is analogous to the TEBP a–b
heterodimer in the ciliated protozoan Oxytricha nova
(Gray et al. 1991; Horvath et al. 1998). A substantial
portion of POT1–TPP1 is associated with the dsDNA-
binding proteins TRF1 and TRF2 through a bridge formed
by TIN2 (Kim et al. 1999; O’Connor et al. 2006; Sarthy
et al. 2009; Takai et al. 2010). A sixth protein, RAP1, is
critical for inhibiting nonhomologous end-joining of
mammalian telomeres (Sarthy et al. 2009). Unlike bud-
ding yeast Rap1 (Konig et al. 1996), themammalian RAP1
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does not bind DNA on its own, but is brought to the
telomere by binding to TRF2. The six-protein mamma-
lian telomere complex has been termed ‘‘shelterin’’ (de
Lange 2005).
In addition to their role in chromosome end protection,
telomeric proteins provide amajor level of telomerase reg-
ulation. In budding yeast, where this regulation has been
studied in great detail, it is mediated by both double-
stranded and single-stranded telomere-binding proteins
(Moretti et al. 1994; Evans and Lundblad 1999; Teixeira
et al. 2004). In human cells, hPOT1 has been reported
to be a telomerase-dependent positive regulator or nega-
tive regulator of telomere elongation (Colgin et al. 2003;
Loayza and De Lange 2003), and TPP1 also contributes to
telomere length control, at least in part by recruitment of
POT1 (Ye et al. 2004).
A detailed mechanistic understanding of the role of
POT1–TPP1 has benefited from studies with purified
proteins. The crystal structure of the POT1–telomeric
DNA complex shows the DNA buried in a groove formed
by twoOB (oligonucleotide-binding) folds (Lei et al. 2004),
and, as expected, this complex is refractory to extension
by telomerase (Kelleher et al. 2005; Lei et al. 2005). When
TPP1 is added, the apparent Kd is decreased by 10-fold,
while the protein-binding site on the DNA is unchanged;
yet, when POT1–TPP1 is bound upstream of the DNA 39
end, leaving a single-stranded 39 tail, telomerase extends
it with enhanced repeat addition processivity (hereafter
termed ‘‘processivity’’) (Wang et al. 2007). That is, mul-
tiple telomeric repeats are synthesized on a single DNA
molecule prior to dissociation. Although it is not straight-
forward to compare in vitro and in vivo results, this en-
hanced processivity means that a single round of telome-
rase action is within a factor of 2 of accounting for the
amount of extension of a telomere seen in a single cell
cycle (Zhao et al. 2009).
We provided evidence that POT1–TPP1 bound to a
DNA primer stimulates telomerase processivity by
two mechanisms: inhibiting primer dissociation from
telomerase, and facilitating the translocation of the
primer/template (Latrick and Cech 2010). These activi-
ties of POT1–TPP1 could be explained if it bound to
telomerase and, in fact, an interaction with TERT has
been reported (Xin et al. 2007). Alternatively, or in ad-
dition, stimulation of processivity might be a DNA sub-
strate-specific effect. For example, the continued interac-
tion of a G-rich portion of the primer with the anchor site
of telomerase might be helpful for initiation but inhibi-
tory to processivity, and POT1–TPP1 binding to the na-
scent DNA could prevent its interaction with the anchor
site. In this study, we develop a new approach involving
mixing and matching telomerase and telomere compo-
nents from different organisms to show that POT1–TPP1
stimulation of processivity does not act at the level of the
DNA substrate, but requires an interaction with telome-
rase. Furthermore, using site-specificmutagenesis,we iden-
tify a site in the TEN (telomerase essential N-terminal)
domain of TERT, in a subregion known as the DAT
(dissociates activities of telomerase) domain (Armbruster
et al. 2001), that is required for this stimulation.
Results
TPP1 activation is species-specific
Telomerase of the fish medaka synthesizes the same
TTAGGG telomeric repeats as human telomerase (Xie
et al. 2008). Its telomerase RNA (TR) has a size and sec-
ondary structure similar to that of human telomerase,
and the two TERT proteins are 36.6% identical and
50.6% similar (Yap et al. 2005; Xie et al. 2008). When
the medaka TERT and TR were expressed in a rabbit
reticulocyte lysate (RRL) and presented with a telomeric
oligodeoxynucleotide and dNTPs, the primer was ex-
tended to give a ladder of telomeric repeats (Fig. 1), as
expected from previous work (Xie et al. 2008). The ex-
tension pattern was similar to that obtained with recon-
stituted human TERT and TR (Fig. 1, cf. lanes 3 and 7).
Because these reactions were performed in a vast excess
of primer over enzyme, the appearance of an extended
ladder of products indicates processivity, as confirmed
rigorously elsewhere (Bryan et al. 2000; Latrick and Cech
2010).
Figure 1. Human POT1–TPP1 bound to a telomeric DNA
primer enhances the processivity of human but not medaka tel-
omerase. TERT and TR were expressed in RRLs and telomerase
was immunopurified. Primer a5 (TTAGGGTTAGCGTTAGGG,
50 nM) has a single base mutation that positions POT1 on the
10 nt at the primer 59 end (Lei et al. 2005). Direct telomerase
assay (1 h) in the presence of 32P-dGTP with primer alone (), or
in the presence of 500 nM POT1 (P), 500 nM TPP1 (T), or 500 nM
of each protein (PT). Lanes +2 and +4 are markers synthesized by
telomerase extension of primer (GGTTAG)3 in the presence of
dGTP only (+2) or dGTP and dTTP but no dATP (+4). They
consistently run slightly higher than the corresponding products
in the experimental lanes because of the slight difference in base
composition of the primers. The numbers 2–30 at left indicate
the number of telomeric repeats synthesized.
Zaug et al.
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When the two telomeraseswere presentedwith a human
POT1–primer complex with a protruding 7-nucleotide (nt)
39 tail, they responded differently. This DNA tail length
was sufficient for extension by human telomerase (Fig. 1,
lane 4), which extended the primer with slightly increased
processivity as documented previously (Lei et al. 2005).
Medaka telomerase, on the other hand, was substantially
but not completely inhibited (90% inhibition) (Fig. 1, lane
8). This inhibition could be overcome by adding excess
primer (Supplemental Fig. 1) or by changing the sequence
of the TR template and primer to a non-POT1-binding
sequence (data not shown), which argue against the POT1
directly inactivating medaka telomerase; presumably, the
human POT1–primer complex is a poor substrate for
medaka telomerase. Human TPP1 alone had little effect
on either medaka or human telomerase (Fig. 1, cf. lanes 3
and 5, and lanes 7 and 9), which is expected because TPP1
by itself does not bind DNA. In the key experiment, TPP1
was unable to stimulate the reaction of medaka telome-
rase on POT1–DNA (in Fig. 1, lane 10 is unchanged from
lane 8). This was in contrast to the positive control with
human telomerase, where POT1–TPP1 consistently gave
more than twofold enhanced processivity (Fig. 1, cf. lanes 6
and 4). (The TPP1 proteins used throughout this study are
the fully active N-terminal portions, TPP1-N [see the
Materials and Methods].)
The medaka versus human telomerase experiments
allow a strong conclusion, because most of the compo-
nents of the two reactions were identical. The same
POT1–TPP1–DNA complex was tested in both cases,
and the components of the RRL were the same. The only
differences were the TERT and TR. If POT1–TPP1 were
acting through binding to the DNA substrate without
interaction with telomerase, it should have affected both
reactions identically. If some component of the RRL were
displacing POT1–TPP1 from the DNA, both reactions
should have been activated. Instead, the different effect
of TPP1 on the two reactions suggests that elements
of TERT or TR that differ between medaka and human
interact with TPP1.
Mutation in the TEN domain prevents TPP1 activation
The TEN domain of TERT has been implicated in pro-
cessivity in human, yeast, and Tetrahymena telomerases
(Moriarty et al. 2004; Autexier and Lue 2006; Zaug et al.
2008). In an attempt to identify a specific region of tel-
omerase involved in a functional interaction with TPP1,
we made a series of single amino acid mutations in the
TEN domain of hTERT and tested them for telomerase
activity with and without POT1–TPP1. We made use of
the crystal structure of the TEN domain of Tetrahymena
TERT (Jacobs et al. 2006); we assumed that conserved
amino acids (see alignment in Supplemental Fig. 2) would
occupy similar positions in the Tetrahymena and human
structures. We then concentrated our mutagenesis on
surface residues (Fig. 2A), where substitutions would be
less likely to disrupt the structure of the TEN domain but
might interfere with putative intermolecular interactions
with TPP1.
Mutations in the TEN domain decreased telomerase
activity to different extents (Figs. 2B, 3A). (Throughout this
study, we use ‘‘activity’’ to indicate the total incorporation
of nucleotides per unit time for a constant amount of
TERT, whereas ‘‘processivity’’ indicates the average num-
ber of repeats added following a single binding event.)
Furthermore, like the wild-type enzyme, most of the
mutants were stimulated slightly when POT1 was bound
to the 59 end of the DNA primer, leaving a 7-nt 39 tail.
There was also slight stimulation by TPP1 alone, a phe-
nomenon that has not been investigated further. In the
presence of both POT1 and TPP1, most mutant telome-
rases extended the DNA with the enhanced processivity
characteristic of wild-type telomerase. Especially dramatic
was Q169A, a mutant of a highly conserved amino acid in
the DNA-binding groove of TEN. Q169A telomerase had
only 4.3% 6 0.6% (mean 6 SEM, n = 5) of wild-type
activity on a naked DNA primer, but, when quantified, it
was clear that both its activity and processivity were
enhanced by POT1–TPP1 (Figs. 2B, 3).
Unique among all the mutants tested was G100V,
because it was unaffected by TPP1. Telomerase activity
was decreased somewhat by the G100V mutation, mea-
sured as 25% 6 3% of wild-type (Fig. 3A). G100V telome-
rase showed some enhancement of activity and processiv-
ity by POT1 alone, but not by TPP1 alone; importantly,
there was no increase of activity or processivity by POT1–
TPP1 relative to POT1 alone (Figs. 2B, 3B–D).WhenG100V
TERT and hTR were overexpressed in human 293T cells
(Cristofari and Lingner 2006), the telomerase assembled in
cells acted just like that assembled in RRLs: It had reduced
activity relative to wild-type telomerase, and there was no
increase of activity or processivity by POT1–TPP1 relative
to POT1 alone (Supplemental Fig. 3).
TEN domain is not sufficient
Given the deleterious effect of the G100V mutation on
telomerase processivity, it seemed possible that the TEN
domain of TERT might be not only necessary but also
sufficient for activation by POT1–TPP1. We therefore
constructed a chimeric TERT that had the human TEN
domain and the remainder of the protein sequence from
medaka. As shown in Figure 4 (lane 5), this chimeric TERT
was activewithmedakaTR, as expected, because its RNA-
binding domain was derived from medaka TERT. It was
not active with the humanTR, suggesting that some of the
TERT–TR interactions involve sequences that differ be-
tween these two homologous systems.
Unlike medaka telomerase, the chimeric human–
medaka telomerase was not inhibited by POT1 bound to
the primer (Fig. 4, cf. lanes 6 and 2). Thus, the proposed
steric hindrance between medaka telomerase and human
POT1 appears to be localized to the TEN domain. Impor-
tantly, when the chimeric human–medaka telomerase was
tested with a POT1–TPP1-bound primer, it gave the normal
ladder of extension products, but did not show the enhanced
processivity seen with human telomerase (Fig. 4, lane
8). Thus, while the TEN domain is necessary for POT1–
TPP1 activation, it is not sufficient. We hypothesize that
Telomerase–telomere protein interaction
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enhanced processivity by POT1–TPP1 requires the TEN
domain to interact productively with some other region
of TERT or TR, and that these interaction partners differ
between human and medaka.
Human and mouse TPP1 activate their respective
telomerases
Having identified a site within human telomerase required
for its functional interaction with human POT1–TPP1, we
wished to explore the specificity with respect to the tel-
omeric proteins. Is the interaction through POT1 or TPP1,
and how species-specific is it? However, the medaka tel-
omeric proteins have not been characterized. We therefore
explored the mouse system, hoping that it would have
diverged enough from the human system to give some
information about specificity of interactions. Indeed, the
mouse has two POT1 proteins, which provide nonover-
lapping functions in telomere maintenance (Hockemeyer
et al. 2006). Furthermore, coimmunoprecipitation experi-
ments indicate that mouse POT1A can form a complex
with human TPP1, and human POT1 with mouse TPP1,
although not as efficiently as the homologous combina-
tions (Hockemeyer et al. 2007).
Mouse POT1A and mouse TPP1 were overexpressed in
Escherichia coli and purified essentially to homogeneity
(Fig. 5A). Themouse POT1Abound to the telomeric primer
a5 used for telomerase assays with a similar equilibrium
dissociation constant as human POT1: Kd = 5 nM (Fig. 5B).
Human TPP1 formed the expected ternary complex with
hPOT1 on a telomeric oligonucleotide, while the hPOT1–
mTPP1 complex was formed inefficiently (Fig. 5C). When
Figure 2. Mutations in the TEN domain of
hTERT uncouple POT1–TPP1 activation from
basal activity. (A) Domain structure of TERTand
crystal structure of the TEN domain of Tetrahy-
mena TERT, shown as a surface representation.
Based on the assumption that conserved amino
acids occupy similar positions in the human
and Tetrahymena proteins, the amino acids that
define the anchor site are shown in red, and
other amino acids mutated in this study are also
colored. The numbering system is given as
Tetrahymena TERT (human TERT). (B) Telome-
rase activity assays for hTERT mutants com-
plexed with hTR. The conditions are the same as
in Figure 1. (C) SDS-PAGE showing the integrity
and equal concentration of the 35S-labeled
hTERT proteins used in B, as well as the medaka
(medWT) and mouse (mWT) TERTs.
Zaug et al.
616 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on August 1, 2014 - Published by genesdev.cshlp.orgDownloaded from 
mTPP1 was substituted for hTPP1 in telomerase assays
containing hPOT1 bound to primer a5, it did not give
stimulation of processivity (Fig. 5D, lane 5 does not show
the high processivity of lane 4, and is instead the same as
hPOT1 alone in lane 2). The lack of functionmay simply be
due to inefficient complex formation by the heterologous
hPOT1–mTPP1 combination.
Human and mouse POT1 bound to similar positions on
the telomeric primer a5, in all cases binding mostly to the
59 end of the DNA, leaving a 7-nt 39 tail (Supplemental
Fig. 4). This tail length is sufficient for human telomerase
to extend a5 DNA bound to hPOT1 (Lei et al. 2005), yet
binding of mouse POT1A to telomeric primer a5 sub-
stantially inhibited telomerase action (Fig. 5D, cf. lane 6
and control lane 1). We do not know if the inhibitory effect
ofmouse POT1Amay involve a non-DNA-binding portion
of POT1A or greater steric hindrance of mouse POT1A.
Mouse TPP1 alone had no effect on telomerase action (Fig.
5D, lane 7 is identical to lane 1), consistent with the fact
that it does not bindDNAby itself. The addition ofmTPP1
did not rescue the inhibition of human telomerase by
mPOT1A (Fig. 5D, lane 8 is identical to lane 6), in stark
contrast to many studies in which hTPP1 promotes the
synthesis of long repeats on hPOT1-inhibited primers
(Wang et al. 2007; Latrick and Cech 2010).
The combination of mPOT1A and hTPP1 gave a strik-
ing result: Telomerase activity was increased by fivefold
relative to mPOT1A alone (Fig. 5D [cf. lanes 9 and 6],
E [top]). Furthermore, processivity was increased signifi-
cantly upon addition of hTPP1 (Fig. 5E, bottom), the 55%
increase being almost as large as the 76% increase seen
upon addition of hTPP1 to the hPOT1 reaction. Thus, the
mPOT1A–mTPP1 combination is functionally incompat-
ible with human telomerase, but the mPOT1A–hTPP1
combination is functional, despite the less efficient com-
plex formation upon substitution of the heterologous
mouse protein (Fig. 5C). The simplest explanation is that
hTPP1 provides a sequence-specific interaction with hu-
man telomerase. We cannot discountmore complexmod-
els, such as hTPP1 inducing a conformational change in
POT1 (both hPOT1 and mPOT1A) and the interaction
Figure 4. Chimeric human–medaka TERT is active but is not
stimulated by hPOT1–TPP1. The chimeric TERT has the TEN
domain of hTERT (amino acids 1–187) fused to the remainder of
medaka TERT (starting with Phe185), reconstituted with me-
daka TR. Lanes 1–4 show activity of wild-type (WT) medaka
TERT–medaka TR for comparison. Primer a5 is at 50 nM; each
protein is at 500 nM as in previous figures.
Figure 3. Quantitation of activity and pro-
cessivity of hTERT mutants confirms the
exceptional nature of G100V. (A) Activity of
mutant telomerases relative to wild type.
Error bars represent standard error, typically
five independent measurements. (B) Change
in activity when primer is bound to hPOT1
(P), hTPP1 (T), or both (PT), with each activity
measurement normalized to the activity of
the same telomerase in the absence of hPOT1
and hTPP1. The wild-type (WT) medaka telo-
merase shown as the last set. (C) Processivity
of mutant telomerases, with standard error as
above. (D) Analysis of processivity from the
gel of Figure 2B, one of the data sets used for
C. Medaka data from the gel of Figure 4. (F)
Fraction of telomerase products extended be-
yond the indicated repeat number. See the
Materials and Methods for details.
Telomerase–telomere protein interaction
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with telomerase then being mediated through the POT1
subunit.
On the basis of our model that TPP1 coevolved with
TERT to stimulate its processivity, we hypothesized that
the mouse POT1–TPP1 complex might stimulate pro-
cessivity of mouse telomerase. The mouse telomerase
core enzyme reconstituted from TERT and TR gives only
a single round of extension in vitro because the RNA has
too short a primer alignment sequence (Supplemental Fig.
5A; Chen and Greider 2003). Binding mouse POT1–TPP1
to the primer does not rescue this defect (Supplemental
Fig. 5B). However,mouse telomerase can be converted into
a processive enzyme by substituting human TR for the
mouse TR, or substituting just the template-containing
pseudoknot domain of hTR, or by two single nucleotide
mutations in the mouse RNA (mTR*) that increase base-
pairing between the primer and the alignment region of
mTR (Chen andGreider 2003).We assembled each of these
hybrid and mutant mouse telomerases and confirmed that
they were active and now gave processive extension (Fig.
6). In all cases, activity was inhibited 75% by binding of
mPOT1A to the primer, analogous to the effect of
mPOT1A on the activity of the human enzyme described
above. However, further binding of mTPP1 not only
reversed this inhibition, but also gave a substantial in-
crease in processivity (2.2-fold increase in the case of the
mTERT–mTR* telomerase) (for other versions of mouse
telomerase, see Fig. 6B). In contrast, the human POT1–
TPP1 did not affect the processivity of the mTERT–mTR*
telomerase (although it did stimulate two of the telo-
merases that contained mTERT and portions of hTR)
(Fig. 6B). Thus, the activation of telomerase processivity
by cognate TPP1 telomere proteins may be a general
feature of telomerase regulation in mammals.
Discussion
In addition to its role in chromosome end-capping, the
POT1–TPP1 telomeric protein complex increases the
processivity of primer elongation by telomerase (Wang
et al. 2007). This activation does not require POT1–TPP1
binding continuously to the nascent ssDNA, but does
require at least one binding site upstream of the part of
the primer that is bound to telomerase’s RNA template
(Latrick and Cech 2010). This activity of POT1–TPP1
suggests a physical interaction with telomerase, but the
interaction may be transient, as our attempts to show
stable binding by pull-down experiments or by photocross-
linking were unsuccessful. Here we took advantage of the
recent discoveries of telomerases and telomeric proteins
Figure 5. Human but not mouse TPP1 can activate
human telomerase even in a heterologous POT1–TPP1
complex. (A) Typical purity of the mouse POT1A and
TPP1 determined by SDS-PAGE. (B) Binding of mouse
POT1A (squares, solid line) and human POT1 (circles,
dashed line) to a trace amount of radiolabeled a5 primer
determined by filter binding. (C) Formation of POT1–
DNA binary complexes and POT1–TPP1–DNA ternary
complexes determined by an electrophoretic mobility
shift assay. Radiolabeled primer T8GGTTAGGGTTAG
(position indicated by arrow), where the eight T nucle-
otides are necessary to reveal the subtle gel shift ob-
tained when TPP1 (an acidic protein) joins the complex.
Human (h) and mouse (m) proteins, each at 50 nM. All
combinations of POT1 and TPP1 gave a stable ternary
complex (indicated by an asterisk to the left of the
band), with complex formation being complete in the
case of human/human (h/h), half-complete in the cases
of mouse/mouse (m/m) and mouse/human (m/h), and
only a low extent in the case of human/mouse (h/m).
(D) Telomerase activity assays with 50 nM primer a5 in
the absence () or presence of telomere proteins (500 nM
each) as indicated. (E) Quantitation of total human
telomerase activity (relative to activity of primer a5 in
the absence of telomere proteins) and of processivity (in
units of number of telomeric repeats) for the data shown
inD and independent experiments not shown. Error bars
represent standard deviation; n = 3.
Zaug et al.
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from other vertebrate species and used mix-and-match
experiments to provide evidence that there is indeed
a specific interaction between human TPP1 and human
telomerase, as well as between mouse TPP1 and mouse
telomerase.
We also tested site-specific mutants of TERT using
telomerase enzymatic assays, an approach that has the
power of identifying functionally important sites even if
they interact only in a short-lived intermediate or in the
transition state. This approach identified the G100V
mutant as having the special property of retaining activ-
ity but being inert to TPP1 activation. G100 is in a sub-
region of the TEN domain of TERT called DAT (Fig.
2A); DAT mutants dissociate two activities of telome-
rase: catalytic activity, and the ability to function in vivo
(Armbruster et al. 2001).
There could be direct contact between TPP1 and the
G100 region of TERT that either prevents the primer from
dissociating during a vulnerable moment in the reaction
cycle or causes an allosteric change in the enzyme con-
formation. However, the sort of genetic evidence we pre-
sent here cannot distinguish a direct interaction from an
indirect interaction. Thus, the interaction partner of TPP1
could be elsewhere, in TERTor TR or both, and that inter-
action could induce a conformational change that involves
G100. Furthermore, even if the interaction is directly
with G100, it cannot be sufficient to activate telomerase;
medaka TERT has a G99 that aligns with human G100
(Supplemental Fig. S2), yet it is unable to respond to POT1–
TPP1. In substantiation of this point, we constructed
a chimeric TERT containing the human TEN domain
fused to medaka RNA-binding and RT domains and found
it to be active, but not further activated by POT1–TPP1.
Furthermore, the activation of telomerase processivity
appears to involve the RNA subunit as well: Note that
mouse telomerase (mTERT–mTR*) was activated only by
mouse POT1–TPP1, but two of the mTERT telomerases
that contained portions of hTR were activated by both
mouse and human POT1–TPP1 (Fig. 6B).
The biological activity of G100V telomerase has been
tested in primary human HA5 cells by David Sealey,
Michael Taboski, and Lea Harrington (pers comm.). The
transfected mutant and wild-type TERT genes were ex-
pressed at approximately the same level as judged by
mRNA analysis, but it was not possible to measure the
TERT protein levels. No G100V telomerase activity
could be detected by the TRAP assay in cell extracts or
after immunopurification, indicating that themutant had
decreased activity; however, the sensitivity of the exper-
iment was such that 25% residual activity could have
gone undetected. Transfection of G100V TERT failed to
immortalize HA5 cells or to maintain telomere length, in
contrast to wild-type TERT. These data clearly indicated
that the G100V mutation was deleterious to telomerase
function in vivo. The data could not distinguish if the
effect was simply at the level of decreased protein sta-
bility, or if substantial amounts of telomerase were as-
sembled but were functionally defective.
One alternativemodel that we can now discount is that
POT1–TPP1 enhances telomerase processivity entirely
through its interaction with the DNA. A priori, such an
explanation would seem quite reasonable. For example,
human telomeric DNA repeats are prone to form
G-quadruplex structures, and these can be deleterious
to telomerase extension (Zahler et al. 1991; Zaug et al.
2005). Binding of POT1 is known to disrupt G quadru-
plexes in favor of formation of the protein–DNA complex
(Zaug et al. 2005), and POT1–TPP1 would be expected to
have the same ability. Or there could be an interaction
between the upstream G-rich sequence and the telome-
rase anchor site that might need to be disrupted to give
maximum processivity, and coating of the DNA with
POT1–TPP1 could prevent such an interaction. However,
Figure 6. Telomerases that contain mouse TERT have their
processivity activated by mouse POT1A–TPP1. (A) Representa-
tive activity data, with 50 nM primer a5 and 500 nM each
indicated protein. All telomerases were comprised of mTERT
plus the RNA indicated; mTR* is full-length mouse TR, with the
asterisk indicating two point mutations in the primer alignment
region that improve primer binding (see Supplemental Fig. 5B).
For other RNAs, numbers represent the nucleotides present in
the transcript. Activity of telomerases in the two left panels was
consistently low, so these data are shown with longer exposure
than in the right panel. (B) Quantitation of telomerase processivity
(in units of number of telomeric repeats) for the data shown in
A and independent experiments not shown. hTR/mTR indicates
a two-piece RNA system consisting of nucleotides 34–192 of hTR
and domains CR4 and CR5 of mTR. Error bars represent standard
deviation; n ranged from 3 to 6.
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any such DNA substrate-level effects should have en-
hanced the activity of both human and medaka telo-
merases. Our finding that medaka telomerase is not ac-
tivated argues against this model.
Recruitment of telomerase by telomere-binding proteins
has been reported in budding yeast, where the telomerase-
associated Est1 protein interacts with the Cdc13 telomeric
DNA-binding protein (Qi and Zakian 2000). Est1–Cdc13
fusion proteins direct yeast telomerase to telomeres, con-
sistent with a natural function of these proteins in me-
diating telomerase access (Evans and Lundblad 1999). A
subregion of the human TEN domain called the DAT
domain, when fused to the telomere DNA-binding protein
TRF2, redirects DAT mutants of TERT to telomeres, sug-
gesting a telomere recruitment function for the DAT
domain (Armbruster et al. 2003). DAT mutants can also
be rescued by fusing the mutant hTERT to hPOT1
(Armbruster et al. 2004). Our new data provide strong sup-
port for the Counter laboratory model (Armbruster et al.
2004) that the DAT domain of TERT mediates telomere–
telomerase association, and they suggest a more detailed
interpretation as follows: Wild-type telomerase may asso-
ciate with telomeres through interaction of the DAT do-
main with TPP1, which in turn binds to POT1, and the
rescue of DAT mutants by fusing the mutant hTERT to
hPOT1 is successful because the fusion supplants the need
for having the TPP1 ‘‘bridge’’ in this interaction. Thus, the
interaction between the G100 region of TERT and TPP1
described here may be involved not only in telomerase
processivity, but also in telomerase recruitment to telo-
meres.
Materials and methods
Mutagenesis
Mutations in the human TEN domain of TERT were made
using the QuickChange II XL site-directed mutagenesis kit
(Stratagene) with primers designed as described in Zheng et al.
(2004).
In vitro reconstitution of telomerase
C-terminal HA-tagged human TERT was expressed from
phTERT-HA2, and hTR was expressed from phTR, using the
TnT quick-coupled transcription/translation system (Promega).
Each 500-mL reaction contained 400 mL of TnT quick mix, 8 mL
of 35S-methionine (Perkin-Elmer), 10 mL of PCR enhancer
(Promega), 10 mL of 1 mM methionine, 10 mg of supercoiled
phTERT-HA2, and 10 mg of hTR, which was transcribed from
Fok I-cut pHTR plasmid DNA, and water to a total of 500 mL.
After incubation for 2 h at 30°C, the reconstituted telomerase
complex was affinity-purified on anti-HA F7 agarose beads (Santa
Cruz Biotechnologies). Anti-HA F7 agarose beads, washed with
13 human telomerase assay buffer (defined below) without KCl,
were added for immunopurification for 2 h at 4°C. The beads
were washed with 13 human telomerase buffer with 30%
glycerol four times and then resuspended in 13 human telome-
rase assay buffer with 30% glycerol. The quantity of 35S-hTERT
was determined. Unused beads were quick-frozen in liquid
nitrogen and stored at 80°C. T7-tagged medaka TERT was
expressed from pCite-MedTERT, medaka TR was expressed from
Fok I-cut pMedTR, and C-terminal HA-tagged mouse TERTwas
expressed from pCite-mTERT (J. Chen, Arizona State Uni-
versity). mTR and mTR* were expressed from PCR-generated
templates using the TnT quick-coupled transcription/translation
system, with other experimental details as described above for
human TERT and TR.
Telomerase activity assays
Activity of the immunopurified human telomerase complex
reconstituted in vitro was determined by a direct assay modified
from a published protocol (Wang et al. 2007). The reaction
mixture (20 mL) contained 13 human telomerase assay buffer
(50 mM Tris-HCl at pH 8.0, 50 mM KCl, 1 mM MgCl2, 5 mM
2-mercaptoethanol, 1 mM spermidine), 0.05 mM telomeric DNA
primer, 0.5 mM dATP, 0.5 mM dTTP, 2.92 mM dGTP, and
0.33 mM 32P-dGTP (3000 Ci/mmol, 1 Ci = 37GBq), with 6 mL
of immunpurified telomerase complex. For medaka TERT telo-
merase assays, the concentration of cold dGTP was increased to
50 mM. Reactions were incubated for 1 h at 30°C, which was
determined to be a time when activity was still increasing with
time, but when processivity had plateaued. Reactions were
stopped with the addition of 100 mL of 3.6 M NH4OAc contain-
ing 20 mg of glycogen. Ethanol (500 mL) was added for pre-
cipitation. After incubating for 1 h at 80°C, samples were
centrifuged for 15 min at 4°C. Pellets were washed with 70%
ethanol and resuspended in 10 mL of H2O followed by 10 mL
of 23 loading buffer (94% formamide, 0.13 TBE, 0.1% bromo-
phenol blue, 0.1% xylene cyanol). The heat-denatured samples
were loaded onto a 10%polyacrylamide/7Murea/13TBEdenatur-
ing gel for electrophoresis. After electrophoresis, the gel was
dried and quantified by using a PhosphorImager (GE Healthcare).
Protein expression and purification
Proteins hPOT1 and hTPP1-N (amino acids 89–334) were
expressed and purified as reported previously (Lei et al. 2004;
Wang et al. 2007). The ORFs encoding mPOT1A and mTPP1-N
(amino acids 1–246) (designed based on sequence alignment with
hTPP1-N) were PCR-amplified from cDNA and cloned into
a pET-His-Smt3 expression vector (Mossessova and Lima 2000).
The proteins were overexpressed in Bl21 (DE3) cells. His-Smt3-
mPOT1A and His-Smt3-mTPP1-N were purified from the solu-
ble cell lysates using Ni-affinity chromatography (Qiagen),
and the His-Smt3 tag was removed. Untagged mPOT1A and
mTPP1-N were further purified by gel exclusion (Superdex200
[GE] and Superdex75 [GE], respectively) and anion exchange
(MonoQ, GE) chromatography, and the fractions containing pure
proteins were flash-frozen in liquid nitrogen and stored at80°C.
Concentrations were determined by the Bio-Rad Protein Assay,
based on the Bradford method; hPOT1 was typically;40%–50%
active and mPOT1Awas typically 25% active, as determined by
quantitative DNA-binding titrations.
Processivity quantitation
The number of counts for each repeat in a lane of a telomerase
activity gel was determined using PhosphorImager scanning and
ImageQuant software. The counts for a band were corrected by
dividing by the total number of radiolabeled guanosines in that
extension product. Then, for each band n, the fraction F of the
chains that continued past n was calculated (Latrick and Cech
2010). The graph of ln F versus repeat number (see examples in
Fig. 3D) was fit with a linear regression, and processivity =
0.693/slope. The first repeat was not included in the fit because
telomerase synthesizes one or two repeats before synthesis is
linear.
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